Cristofanilli M, Slamon DJ, Ro J, et al. Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3. ESMO 2018, abstract LBA2_PR.
PARP-remmers: een nieuw tijdperk in de behandeling van (recidiverende) ovariumkanker
aug 2020 | Gynaecologische oncologie